Oral Propranolol for Hemangiomas of Infancy

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2010;16(8) 

In This Article

Clinical Trials

Six trials of oral beta-adrenergic blocking agents for treatment of infantile hemangiomas are listed on the National Institutes of Health clinical trials registry, www.clinicaltrials.gov (accessed 7/31/10). Five of the trials are currently enrolling patients, including four randomized comparison trials with propranolol and a trial evaluating the efficacy of nadolol. Two placebo-controlled propranolol studies are being conducted by Léauté-Labréze and colleagues, authors of the initial case series. The first study is scheduled to conclude patient enrollment by the end of the year. A larger international study, The Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants with Proliferating Infantile Hemangiomas Requiring Systemic Therapy, is also currently enrolling patients.

Additional studies comparing oral propranolol to prednisone or prednisolone are being conducted at Seattle Children's Hospital, Children's National Medical Center in Washington D.C., and the University of Sao Paulo in Brazil. The Hospital for Sick Children in Ontario, Canada is studying the utility of nadolol, another non-selective beta-adrenergic blocking agent, in this patient population. Expected completion dates range from December 2010 to July 2013. The results of these clinical trials should provide more definitive information on the efficacy and safety of this therapeutic class in the treatment of hemangiomas.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: